Your mission, our focus
We accelerate treatments to clinical trials within 24 months, and our collaborations with patient groups have been key to that success
Rare Treatment Accelerator
Our Rare Treatment Accelerator programme connects academic, patient and industry groups with Healx. Working together, we can quickly turn your research, insights and clinic-ready repurposing assets into treatments that will benefit rare disease patients.Learn more
Intelligent, collaborative, efficient
We use AI to accelerate drug discovery and development, but we accelerate it even more by focusing on repurposing known drugs. By saving time, we also save money. One of the greatest benefits, however, is the safety these known drugs have already shown in late-stage trials.
The right technology
Our AI platform Healnet delivers its predictions by leveraging various public and proprietary datasets. If necessary, Healnet can also extract information from those datasets to fill in critical gaps in what we know about certain rare diseases. Our experts always validate these inferences and the opportunities they bring to light.
Dr Bruce Bloom
Patient groups, patients and carers have insights, resources and relationships that can multiply the speed and value of our AI therapy discovery. We need each other to make quick progress for rare disease patients.
Dr Michael Tranfaglia
The Healx partnership has been nothing short of amazing. In less than two years together, we were able to deliver decades-worth of drug discovery, and now we’re taking those discoveries to the clinic.
Dr Rick Thompson
Healx combine a deep knowledge of drug repurposing with a passionate desire to deliver real change to rare disease patients.
Dr Cesare Spadoni
Healx changed my perception of what's possible in drug development.
AI-powered repurposing versus conventional drug development
From discovery to clinic
Schuhmacher A et al. (2016) Changing R&D Models in Research-Based Pharmaceutical Companies. Journal of Translational Medicine.